An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland, who have been prescribed Sativex® (THC:CBD, nabiximols) oromucosal spray

• Main Authors: Etges T (Author), Karolia K (Author), Grint T (Author), Taylor A (Author), Lauder H (Author), Daka B (Author), Wright S (Author)
• Format: Book
• Published: Dove Medical Press, 2016-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Tilden Etges, Kari Karolia, Thomas Grint, Adam Taylor, Heather Lauder, Brian Daka, Stephen Wright GW Pharmaceuticals, Cambridge, UK Abstract: The global exposure of Sativex® (Δ9-tetrahydrocannabinol [THC]:cannabidiol [CBD], nabiximols) is estimated to be above 45,000 patient-years...